Arbutus Biopharma Corp. (NASDAQ:ABUS)’s share price shot up 3.5% during trading on Friday . The company traded as high as $3.84 and last traded at $3.81, with a volume of 65,485 shares trading hands. The stock had previously closed at $3.68.

A number of research firms have commented on ABUS. Zacks Investment Research lowered shares of Arbutus Biopharma Corp. from a “buy” rating to a “hold” rating in a research report on Friday, April 22nd. Wedbush restated an “outperform” rating and issued a $20.00 price target on shares of Arbutus Biopharma Corp. in a research report on Friday, April 22nd. Leerink Swann restated a “buy” rating and issued a $12.00 price target on shares of Arbutus Biopharma Corp. in a research report on Thursday, May 5th. Finally, Chardan Capital began coverage on shares of Arbutus Biopharma Corp. in a research report on Monday, May 16th. They issued a “sell” rating and a $3.25 price target on the stock. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. Arbutus Biopharma Corp. has an average rating of “Hold” and an average price target of $9.79.

The stock has a 50-day moving average price of $3.95 and a 200 day moving average price of $3.94. The company’s market cap is $207.58 million.

Arbutus Biopharma Corp. (NASDAQ:ABUS) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by $0.36. Equities research analysts anticipate that Arbutus Biopharma Corp. will post ($3.28) EPS for the current fiscal year.

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.